You need to sign in or sign up before continuing.
The Journal of clinical endocrinology and metabolism
The most recent articles from:
March 2014
-
J. Clin. Endocrinol. Metab. · Mar 2014
Observational StudyHyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.
Polycystic ovary syndrome (PCOS) is a triad of anovulation, insulin resistance, and hyperandrogenism. Androgen excess may correlate with metabolic risk and PCOS consensus criteria define androgen excess on the basis of serum T. Here we studied the utility of the androgen precursor serum androstenedione (A) in conjunction with serum T for predicting metabolic dysfunction in PCOS. ⋯ Simultaneous measurement of serum T and A represents a useful tool for predicting metabolic risk in PCOS women. HA levels are a sensitive indicator of PCOS-related androgen excess.